Iowa Hematology Oncology Conference: Emphasis on Precision-Guided Management
The "Iowa Hematology Oncology Conference: Emphasis on Precision-Guided Management" is an accredited continuous education to improve the care of cancer patients by educating cancer care providers about precision-guided management in hematology and oncology. Regional and national experts in the field will share comprehensive insights into the actionable molecular variations seen in common cancers. The event's format is tailored to promote active learning, enhance knowledge retention, and encourage practitioners to apply fresh insights into their clinical routines. Through didactics, case-centric discussions, and lively Q&A sessions, attendees can gain clarity, address uncertainties, and interact with hematology and oncology experts. This conference aims to provide physicians, physician assistants, nurse practitioners, pharmacists, nurses, and other healthcare professionals with the latest updates in precision-guided management in hematology and oncology. It will highlight a multidisciplinary approach and the integration of new advances in patient-centered care.
Target Audience
- Hematologists/ Oncologists
- Oncology Fellows
- NPs/PAs
- Pharmacists
- Nurses
- Researchers and others
ORGANIZING COMMITTEE
Conference Director:
Binay Shah, MD, MHA - Binaytara Foundation
Conference Chair:
Vishal Vashistha, MD - US Department of Veterans Affairs
Organizing Committee
Kartik Anand, MD - Mission Cancer+Blood
Amy Raedeker DNP, ARNP, AGACNP-BC, AOCNP - Mission Cancer+Blood
Maddie Koppin, PharmD - Mission Cancer+Blood
VENUE INFORMATION
A limited number of rooms have been booked at the Embassy Suites by Hilton Des Moines Downtown at a discounted nightly rate of $169 per room for this conference's attendees and sponsors. Please book your room at the link here by February 20, 2024 to receive the discounted group rate.
Learning Objectives
- Review common molecular abnormalities in various cancers and the optimal timing to test for these abnormalities.
- Interpret the findings from next-generation sequencing and other biomarkers that indicate the likelihood of response to specific therapies while also understanding the inherent challenges.
- Apply optimal strategies centered on molecular-targeted treatments in the management of patients with cancer.
- Summarize emerging research, the mechanism of action, and the significance of new molecular-targeted treatments in managing cancer patients.
GLOBAL ONCOLOGY PROJECT
To learn more about our ongoing project building a 200-bed cancer hospital in Nepal:
March 23rd, 2024
All times are listed in Central Time (CT)
07:00 AM – 08:00 AM Registration, Breakfast, & Exhibits
08:00 AM – 08:05 AM Welcome
08:05AM – 08:25 AM Binaytara Foundation's Efforts in Improving Cancer Care Disparities - Binay Shah, MD, MHA
08:25 AM – 09:10 AM Session 1 - Precision Oncology - General Concepts
Moderator: Mark Klein, MD
08:25 AM – 08:40 AM Solid Tumor Genomic Testing - Vishal Vashistha, MD
08:40 AM – 08:55 AM MRD in Hematologic Malignancies - Tara Graff, DO, MS
08:55 AM – 09:10 AM Q and A
09:10 AM – 09:40 AM Session 2 - GI Oncology
Moderator: Chandrikha Chandrasekharan, MBBS
09:10 AM – 09:25 AM Keynote Lecture: Precision Guided Management of GI Cancers - Mridula Krishnan, MBBS
09:25 AM – 09:40 AM Q and A
09:40 AM – 10:25 AM Break & Exhibits
Product Theater Sponsored by Servier Pharmaceuticals in Mississippi Room
Topic: IDHentifying Appropriate MDS or AML patients to Treat With TIBSOVO (Ivosidenib tablets)
Speaker: Harry Erba, MD, PhD - Director of Leukemia Program at Duke Blood Cancer Center
*Non CME Activity*
10:25 AM – 11:25 AM Session 3 - Breast Cancer
Moderator: Seema Harichand, MD
10:25 AM – 10:40 AM Genomics in Breast Cancer - Sneha Phadke, DO, MPH
10:40 AM – 11:25 AM Panel Discussion - Amulya Yellala, MBBS, MD
11:25 AM – 12:25 PM Lunch & Exhibits
11:40 AM to 12:45 PM: Product Theater Sponsored by AstraZeneca in Mississippi Room
Topic: Lunch & Learn TRUPAQ
Speaker: Amy Krie, MD Allina Health Cancer Institute, Piper Breast Center
*Non CME Activity*
12:25 – 01:25 PM Session 4 - GU Oncology
Moderator: Kartik Anand, MD
12:25 PM – 12:40 PM Keynote Speech: Recent Advances in Molecular Guided Treatment of GU Malignancies - Yousef Zakharia, MD
12:40 PM – 01:25 PM Panel Discussion - Bilal Rahim, MD; Benjamin Teply, MD; Nicholas Zorko, MD
01:25 PM – 02:25 PM Session 5 - Lung Oncology
Moderator: Apar Ganti, MD
01:25 PM – 01:40 PM Keynote Speech: Advances in Precision-guided Management of Lung Cancers - Muhammad Furqan, MD
01:40 PM – 02:25 PM Panel Discussion - William Zeitler, MD; Mark Klein, MD; Robert Kratzke, MD
02:25 PM – 02:55 PM Break & Exhibits
02:55 PM – 04:15 PM Session 6 - Hematology
Moderator: James Armitage, MD
02:55 PM – 03:10 PM Multiple Myeloma - Christopher Strouse, MD
03:10 PM – 03:25 PM Myeloid Disorders - Vijaya Raj Bhatt, MBBS, MS
03:25 PM - 03:40 PM CLL - Eric Mou, MD
03:40 PM – 04:15 PM Panel Discussion - Tara Graff, DO, MS
04:15 PM - 04:20 PM Adjourn
A limited number of rooms have been booked at the Embassy Suites by Hilton Des Moines Downtown at a discounted nightly rate of $169 per room for this conference's attendees and sponsors. Please book your room at the link here by February 20, 2024 to receive the discounted group rate.
IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:
All conflict of interest has been identified and mitigated for individuals in control of contents.
PLANNING COMMITTEE DISCLOSURE STATEMENT:
None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.
Binay Shah, MD, MHA
Vishal Vashistha, M.D.
Apar Kishor Ganti, MD
Seema Harichand-Herdt
Mark Klein, M.D.
Vijaya Bhatt, MBBS, MS
Chandrikha Chandrasekharan, MBBS
Muhammad Furqan
Tara Graff, DO MS
Robert Kratzke, Professor of Medicine
Mridula Krishnan
Eric Mou
Sneha Phadke, DO, MPH
Christopher Strouse, MD
Benjamin Teply, MD, MS
Amulya Yellala, MBBS, MD
Yousef Zakharia, MD
William Zeitler
Nicholas Zorko, MD, PhD
Nicholas Zorko, MD, PhD
Jim Armitage, M.D.
Kartik Anand, MD
Madison Koppin, PharmD
Amy Raedeker
Bilal Rahim, MD, MSc
Available Credit
- 5.50 ABIM MOC IISuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
- 5.50 AMA PRA Category 1 Credit™The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 5.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 5.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
- 5.50 Nursing Contact HoursProvider approved by the California Board of Registered Nursing, Provider # CEP17035, for 5.50 Contact Hours.
Platinum Sponsor:
We would like to thank the following exhibitors and sponsors for their support of this meeting.
Name | Table Number | Exhibit type | Rep Name | |
Abbvie | 2 | General Exhibit | Scott Vance | |
Agios | 3 | General Exhibit | Scott Milanowski | |
Alexion Astra Zeneca Rare Disease | 4 | General Exhibit | Kelly Sigle | |
Amgen Onoclogy | 5 | General Exhibit | Nicole Bailey | |
Astellas | 6 | General Exhibit | Val Lang | |
Astrazeneca Table 1 | 1 | General Exhibit | Tom Wolfe | |
Astrazeneca Table 2 | 24 | Lunch PT & Premium Exhibit | Cindy Curtis | |
Boehringer Ingelheim Oncology | 7 | General Exhibit | Raul Jalmasco | |
Bristol Myers Squibb | 8 | General Exhibit | Monica Taylor | |
Daiichi Sankyo | 9 | General Exhibit | Max Rustan | |
Daiichi Sankyo - 2nd table | 11 | General Exhibit | Craig Marker | |
Eisai | 12 | General Exhibit | Gregg Lucken | |
Eli Lilly and Company/Loxo@Lilly | 13 | General Exhibit | Philip M Rocca, Jr. | |
Exelixis | 14 | General Exhibit | Stacey Vance | |
GENENTECH, A MEMBER OF THE ROCHE GROUP | 15 | General Exhibit | CHRIS HINK | |
Genmab | 16 | General Exhibit | Lindy Melcher | |
Gilead Sciences | 23 | Premium Exhibit | Jacqui Hansen | |
Glaxo Smith Kline | 40 | General Exhibit | Renae VanZuiden | |
ImmunoGen | 18 | General Exhibit | Carrie McGuire | |
Ipsen Biopharma | 19 | General Exhibit | Julie Bathke | |
Johnson & Johnson - - 3rd table | 20 | General Exhibit | Carey Nahas | |
Johnson & Johnson - 2nd table | 34 | General Exhibit | Tara Branecki | |
Johnson and Johnson Solid Tumor | 42 | General Exhibit | Catherine Mixsell | |
Menarini Stemline | 21 | General Exhibit | John Rysavy | |
Merck - table 1 | 22 | General Exhibit | Jennifer Coe | |
Merck - table 2 | 25 | General Exhibit | Rob Kloewer | |
Mirati Therapeutics- a Bristol-Myers Squibb Company | 26 | General Exhibit | Jennifer Gau | |
Natera | 27 | General Exhibit | Lawrence O'Brien | |
Novartis Oncology | 28 | General Exhibit | Krista Zepeda | |
Pfizer | 29 | General Exhibit | Mary Bender | |
Pfizer Inc | 30 | General Exhibit | Timothy Devine | |
Pharmacyclics | 31 | General Exhibit | Amy Marshall Freeman | |
Seagen | 32 | General Exhibit | Nicole Lester-Ekis | |
Secura Bio | 33 | General Exhibit | Brenda Dickel | |
Servier | 35 | Break PT & Premium Exhibit | Teresa Nissen | |
SpringWorks Therapeutics | 36 | General Exhibit | Kevin Madoch | |
Taiho Oncology | 37 | General Exhibit | Cynthia Sudekum | |
Takeda Oncology | 38 | General Exhibit | Stacia McGrath | |
Tempus | 39 | General Exhibit | Mitch Gonzales |
Price
POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE:
All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place.
The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference. The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees.
If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.
Violating this policy will result in a fine equivalent to a general display fee for that conference.
If your company has purchased an exhibit or sponsorship, please register at the link below to receive the discounted registration fees:
Link to register as an additional rep of a sponsoring company: https://education.
NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:
If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:
- If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
- If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event.
- If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event.
Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.
CANCELLATION POLICY
You may cancel your enrollment at any time. Cancellation fees apply as below:
- 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
- No refunds will be issued if registration is canceled after that date.
No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.